key: cord-0078835-czz0x14n authors: Toapanta, Néstor; Jiménez, Sara; Molina-Gómez, María; Maruri-Kareaga, Naroa; Llinàs-Mallol, Laura; Villanego, Florentino; Facundo, Carme; Rodríguez-Ferrero, Marisa; Montero, Nuria; Vázquez-Sanchez, Teresa; Gutiérrez-Dalmau, Alex; Beneyto, Isabel; Franco, Antonio; Vicente, Ana Hernández; Pérez-Tamajon, M Lourdes; Martin, Paloma; Ramos-Verde, Ana María; Castañeda, Zaira; Bestard, Oriol; Moreso, Francesc title: Induction immunosuppression and outcome in kidney transplant recipients with early COVID-19 after transplantation date: 2022-04-30 journal: Clin Kidney J DOI: 10.1093/ckj/sfac112 sha: 808c9bcb24c80f1839bc91e75912d59199ff6b67 doc_id: 78835 cord_uid: czz0x14n COVID-19 in kidney transplants has a high risk of complications and mortality, especially in older recipients diagnosed during the early period after transplantation. Management of immunosuppression has been challenging during the pandemic. We investigated the impact of induction immunosuppression, either basiliximab or thymoglobulin, on the clinical evolution of kidney transplants developing COVID-19 during the early period after transplantation. Kidney transplant recipients with less than 6 months with a functioning graft diagnosed of COVID-19 from the initial pandemic outbreak (March 2020) until July 31st, 2021 from different Spanish centers participating in a nationwide registry. A total of 127 patients from 17 Spanish centers developed COVID-19 during the first 6 months after transplantation, 73 (57.5%) received basiliximab and 54 (42.5%) thymoglobulin. Demographics were not different between groups but patients receiving thymoglobulin were more sensitized (cPRA of 32.7±40.8% vs. 5.6±18.5%) and were more frequently re-transplants (30% vs. 4%). Recipients older than 65 years treated with thymoglobulin showed the highest rate of acute respiratory distress syndrome (64.7% vs. 37.1% for older recipients receiving thymoglobulin and basiliximab [p<0.05], and 23.7% and 18.9% for young recipients receiving basiliximab and thymoglobulin [p>0.05]) and the poorest survival (mortality rate of 64.7% and 42.9% for older recipients treated with thymoglobulin and basiliximab, respectively [p<0.05], and 8.1% and 10.5% for young recipients treated with thymoglobulin and basiliximab [p>0.05]). Older recipients treated with thymoglobulin showed the poorest survival in the Cox's regression model adjusted for comorbidities. Thus, thymoglobulin should be used with caution in older recipients during the present pandemic era. The data collection included recent kidney transplant recipients (less than 6 months) who had been diagnosed of COVID-19 from the start of the (table 3) . Furthermore, DGF did also independently correlate with patient death. Patients treated with thymoglobulin showed a lower number of circulating lymphocytes at the time of diagnosis (table 1) . Linear mixed models for repeated measures showed than lymphopenia tended to recover in both groups of patients as the infection evolved but the recovery was slower in patients treated with thymoglobulin than in patients treated with basiliximab ( figure 4) . Acute phase reactants and D dimer were not different between groups at baseline (table 1) and during the first month (data not shown). As expected, baseline acute phase reactants (interleukin-6 and C reactive protein) and D dimer levels were closely associated with survival. In the present study we analyzed a cohort of renal transplant recipients with COVID-19 diagnosis early after transplantation (less than 6 months). As it has been previously reported, we confirmed that recipients older than 65 years with a higher comorbidity burden showed a higher mortality than younger patients. Remarkably, among older recipients, thymoglobulin induction therapy was an independent factor predicting higher risk of ARDS and death. As expected, lymphopenia was significantly more profound in patients treated with thymoglobulin than in those treated with basiliximab. In Spain, the standard of care for renal transplant recipients receiving a kidney from a brain death or living donor is based on induction therapy with basiliximab whereas thymoglobulin is restricted to high immunological risk transplants. However, management of induction immunosuppression in the case of donors after controlled circulatory death is rather heterogeneous (7). The standard of care for maintenance immunosuppression is tacrolimus, mycophenolate and steroids but some centers have moved to a maintenance regimen based on tacrolimus and mTOR inhibitors (8) . Our set of patients, containing one third of transplants from donors after circulatory death, reflects these heterogenous policies and includes a significant number of patients treated with both induction regimens. In this study cohort, the nosocomial acquired infection was highly prevalent (44%), especially during the first and second waves, indicating that infection was acquired during the first admission or after re-admission due to transplant-related complications. Since the beginning of the pandemics, patient age and comorbidities associated with aging have been repeatedly associated with outcomes after COVID-19 in both, the general population (9) and in renal transplant recipients Kidney transplantation and COVID-19 renal and patient prognosis Predictors of severe COVID-19 in kidney transplant recipients in the different epidemic waves: Analysis of the Spanish Registry Early Changes in Kidney Transplant Immunosuppression Regimens During the COVID-19 Pandemic Kidney transplantation using lymphocyte depleting induction and standard maintenance immunosuppression at the height of the SARS-CoV-2 pandemic in New York City: A single-center experience COVID-19 in transplant recipients: The Spanish experience Organ Donation and Transplantation During the COVID-19 Pandemic: A Summary of the Spanish Experience Early outcomes of kidney transplantation from elderly donors after circulatory death (GEODAS study) Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation A Cohort of Patients with COVID-19 in a Major Teaching Hospital in Europe COVID-19 in elderly kidney transplant recipients Outcomes of COVID-19 in solid organ transplant recipients: A matched cohort study Outcomes of COVID-19 in Solid Organ Transplant Recipients: A Propensity-matched Analysis of a Large Research Network A retrospective matched cohort single-center study evaluating outcomes of COVID-19 and the impact of immunomodulation on COVID-19-related cytokine release syndrome in solid organ transplant recipients COVID-19 severity in kidney transplant recipients is similar to nontransplant patients with similar comorbidities COVID-19 in Solid Organ Transplantation: A Matched Retrospective Cohort Study and Evaluation of Immunosuppression Management Is COVID-19 infection more severe in kidney transplant recipients? COVID-19-related Mortality During the First 60 Days After Kidney Transplantation Annual Data Report: Kidney BMI: body mass index; cPRA: calculated panel reactive antibodies; TAC: Tacrolimus; MMF: Mycophenolate; P: prednisone; DGF: delayed graft function We thank all medical doctors working in the participating Renal Transplant Units for its contribution. None to be declared.